Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

32.65 +1.67 (+5.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Key Takeaways From Guardant Health Analyst Ratings
Via Benzinga
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q2 2024
GH stock results show that Guardant Health beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Assessing Guardant Health: Insights From 7 Financial Analysts
Via Benzinga
Where Guardant Health Stands With Analysts
Via Benzinga
Evaluating Guardant Health: Insights From 5 Financial Analysts
Via Benzinga
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat
The company expects stronger second-half sales vs. the first half of 2024. 
Via Investor's Business Daily
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The strugglingh stock investor did a little bit of shopping on Tuesday, adding to some of her existing positions. 
Via The Motley Fool
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
FDA approves Guardant Health's Shield blood test for colorectal cancer screening in adults 45+, marking the first FDA-approved blood test as a primary CRC screening option. Shield meets Medicare... 
Via Benzinga
Exposures Product Safety
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
From Guardant Health, Inc.
Via Business Wire
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns
The investment banking firm says these companies are among the best stocks to buy and have some strong tailwinds behind them. 
Via InvestorPlace
3 Precision Medicine Stocks Tailoring Treatments
With technological developments pushing the boundaries of healthcare, these are the precision medicine stocks to consider. 
Via InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
Via Benzinga
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts. 
Via InvestorPlace
The 3 Best Personalized Medicine Stocks to Buy in July 2024
Explore promising personalized medicine stocks poised for growth as the industry expands, driven by advancements in genomic technologies. 
Via InvestorPlace
From ‘Sell’ to ‘Strong Buy’: 3 Dramatic Analyst U-Turns to Watch
These are three stocks with analyst upgrades worth looking into thanks to their niche specializations and long-term prospects. 
Via InvestorPlace
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
From Guardant Health, Inc.
Via Business Wire
Guardant Health Named to TIME100 Most Influential Companies
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir 
Via Benzinga
Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns
We're heading into our third year of this raging bull market, and there doesn't appear to be any end in sight for these high-return stocks. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.